May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Subconjuntival Avastin (Bevacizumab) Reverses Corneal Neovascularization
Author Affiliations & Notes
  • H. Harooni
    Ophthalmology, Medical College of Georgia, Augusta, Georgia
  • B. Ambati
    Ophthalmology, Medical College of Georgia, Augusta, Georgia
  • Footnotes
    Commercial Relationships H. Harooni, None; B. Ambati, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1705. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. Harooni, B. Ambati; Subconjuntival Avastin (Bevacizumab) Reverses Corneal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1705.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: To report the effects of subconjunctival Avastin in a series of patients with corneal neovascularization.

Methods:: A retrospective chart review of five patients with acute or chronic corneal neovascularization in the setting of graft rejection in penetrating keratoplasty (n = 2), lamellar keratoplasty (n = 1), neurotrophic keratitis (n = 1), and KID syndrome (n = 1) were given 1-4 subconjunctival injections of 1.25 mg Avastin in 0.01 cc diluent adjacent to the site of neovascular pannus. Patients were then followed (mean 4 months) to document the effects of the Avastin on corneal neovascularization and visual acuity.

Results:: Improvement in corneal neovascularization (as evidenced by partial regression of vessels or the presence of ghost vessels) and ≥ 1 line of Snellen visual acuity were noted in 3 patients. Stable neovascularization and Snellen visual acuity were noted in one patient. One patient was lost to follow-up. No adverse outcomes related to subconjunctival injection of Avastin have been noted to date.

Conclusions:: Despite the small number of enrolled patients, Avastin appears to be a safe and possibly effective treatment for corneal neovascularization. This series suggests a potential role for Avastin in the treatment of ocular surface disease which will require validation by prospective randomized clinical trials.

Keywords: cornea: clinical science • neovascularization 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.